Insecticides IndiaQ3 FY24

Insecticides India Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹545.5P/E: 13.0Market Cap: ₹1.6K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • The company expects a decent double-digit growth every year in sales and revenues.
  • Around half a dozen new product launches, including new technicals and biologicals, are planned annually to drive growth.
  • Biological segment growth is expected to be gradual, targeting INR10-15 crores incremental revenue in early years.
  • Focus on launching IP-protected, new generation solutions with less competition to create strong brands.
  • Volume growth is anticipated alongside price pressures, with double-digit volume growth seen in the current year continuing.
  • The Maharatna and Focused Maharatna product categories are key growth drivers, with focus to increase their contribution to 65-70% of sales in 2-3 years.
  • Export and B2B segments are also expected to grow, supported by new registrations and product introductions.
  • Overall, the company is confident of growing better than the industry with improved top line and bottom line performance in coming years.

See what Insecticides India management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The management did not explicitly mention any current or future plans for fundraising through debt or equity in the discussed sections.
  • Rajesh Aggarwal highlighted that the company is currently debt-free and has sufficient funds to support growth and investments.
  • Focus is on internal growth, new product launches, backward integration, and R&D to improve margins and scale.
  • There was no indication of plans to raise additional capital externally; instead, growth and expansion are being funded through existing resources and operational cash flows.

See what Insecticides India management said on order book — free account, 30 seconds.

Capex plans

Yes
  • The company is focusing on expanding its manufacturing capabilities, including increasing the number of reactors from around 150 to roughly 300 for manufacturing technicals and backward integration.
  • New technicals are being introduced; eight technicals are being stopped while six new technicals are planned for the domestic market within 3-4 months.
  • Investment is made in strengthening teams across marketing, strategy, manufacturing, R&D, and the Board by adding senior professionals.
  • Major insecticides manufacturing will move to the Chopanki plant to improve returns.
  • The company is investing in digitization through a program named IL360 to improve last-mile connectivity with retailers and farmers for better market reach.
  • R&D spend is expected around INR12 to 15 crores next year, with major investment coming from the Japanese partner.
  • Plans to launch new patented products and import more from Japan (Nissan partnership), targeting INR500+ crores in sales from Japanese products next year.

Track Insecticides India — get its next earnings analysis in your feed

How does Insecticides India rank vs peers in Fertilizers & Agrochemicals?

Pro feature
ThisInsecticides India
Rev 3Mar 3

How does Insecticides India rank in Fertilizers & Agrochemicals?

Compare Insecticides India against every Fertilizers & Agrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

Others in Fertilizers & Agrochemicals this season

  • Madhya Bharat Agro Products (Q2 FY27)

    Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo

  • Dhansa Labs (Q2 FY27)

    1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Aristo Bio-Tech (Q2 FY27)

    1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu

  • Krishana Phoschem (Q2 FY27)

    Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →